Adjuvant chemotherapy in elderly patients with breast cancer: where are we?

Purpose of review Breast cancer in elderly patients is a major health concern that will only increase in the future. For early-stage breast cancer, adjuvant chemotherapy may be indicated in this patient group following adequate local treatment and before possible hormone therapy. This review summarizes the current knowledge and provides guidelines for the use of adjuvant chemotherapy in elderly patients with breast cancer. Recent findings Most data are extracted from large multicenter trials with upper age limits of 65 or 70 years. Only one multicenter randomized study investigated the potential benefit of an adjuvant anthracycline-based chemotherapy regimen added to endocrine treatment after the age of 65 years. Retrospective analyses from international group databases show the same potential absolute benefit derived from adjuvant chemotherapy in elderly compared with younger patients, however. This benefit must be weighed against life expectancy and tolerability of chemotherapy. Summary Limited confidence of medical oncologists with cytotoxic chemotherapy administration to the elderly and a lack of both prospective studies and shared guidelines for decision making in this subpopulation are the main factors responsible for the limited use of adjuvant chemotherapy in elderly patients with breast cancer. Fortunately this contrasts with an increasing awareness among clinicians, who should learn to integrate absolute benefit, life expectancy, and tolerance of chemotherapy in their clinical decisions. Discrimination on the basis of older age alone is no longer acceptable.